Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR3 |
| Variant | L608V |
| Impact List | missense |
| Protein Effect | unknown |
| Gene Variant Descriptions | FGFR3 L608V lies within the protein kinase domain of the Fgfr3 protein (UniProt.org). L608V has been identified in the scientific literature (PMID: 28034880, PMID: 37377403), but has not been biochemically characterized and therefore, its effect on Fgfr3 protein function is unknown (PubMed, Aug 2025). |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR3 mutant FGFR3 L608V |
| Transcript | NM_000142.5 |
| gDNA | chr4:g.1805926T>G |
| cDNA | c.1822T>G |
| Protein | p.L608V |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| XM_006713873 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_047449823.1 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_047449824.1 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| NM_000142.4 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_006713873.2 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| XM_006713873.1 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| NM_000142.5 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| NM_000142 | chr4:g.1805926T>G | c.1822T>G | p.L608V | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 L608V | Advanced Solid Tumor | decreased response | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Truseltiq (infigratinib) in culture (PMID: 28034880). | 28034880 |
| FGFR3 L608V | Advanced Solid Tumor | sensitive | Ponatinib | Preclinical - Cell culture | Actionable | In a preclinical study, Iclusig (ponatinib) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880). | 28034880 |
| FGFR3 L608V | Advanced Solid Tumor | sensitive | Dovitinib | Preclinical - Cell culture | Actionable | In a preclinical study, Dovitinib (TKI258) inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880). | 28034880 |
| FGFR3 L608V | Advanced Solid Tumor | decreased response | Fexagratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Fexagratinib (AZD4547) in culture (PMID: 28034880). | 28034880 |
| FGFR3 L608V | Advanced Solid Tumor | decreased response | Zoligratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880). | 28034880 |
| FGFR3 L608V | Advanced Solid Tumor | sensitive | FIIN-2 | Preclinical - Cell culture | Actionable | In a preclinical study, FIIN-2 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880). | 28034880 |
| FGFR3 L608V | Advanced Solid Tumor | sensitive | LY2874455 | Preclinical - Cell culture | Actionable | In a preclinical study, LY2874455 inhibited proliferation of transformed cells over expressing FGFR3 L608V in culture (PMID: 28034880). | 28034880 |